Table of contents
June 2020 - Volume 79 - Suppl 1
- Scientific Abstracts
- Oral Presentations
- tsDMARD therapy of rheumatoid arthritis
- Cardiovascular risk and management in IMIDS
- Detection of type I interferon – Bridges into clinical applications
- Metabolic pathways during the regulation of inflammation and immunity
- How to build and choose an appropriate outcome measure
- Opening Plenary abstract session
- Biological DMARDs in RA I
- Vasculitis
- Lung diseases and other comorbidities in RA
- Pathogenic insights transforming the treatment of Sjön’s and SLE 2020 and beyond
- Psoriatic arthritis and its management: it’s more than just synovitis …
- Artificial intelligence and machine learning in imaging of rheumatology: Are we ready?
- Epidemiology
- What is new in axial spondyloarthritis: clinical and imaging outcomes?
- Pain pathology, progression and pharmacotherapy
- SLE, Sjön's and APS clinical aspects
- New technologies in basic research
- Immunodeficiency and autoimmune disease
- Spondyloarthritis - treatment
- Rheumatoid arthritis - prognosis, predictors and outcome I
- Cardiovascular disease and malignancies in RA
- Immunity in rheumatic diesease
- Connective tissue diseases - genomics, proteomics and pathogenesis
- Vasculitis
- Innovative care
- Advances in treating SLE and lupus nephritis
- Crystals and bones: A selection of best abstracts
- Diagnostics and imaging procedures
- Osteoarthritis: clinical
- Dendritic cells as therapeutics
- Creating in vitro patients - how to best model disease
- Making rational the therapeutic approach to Still’s disease in children and adults
- Multiple issues in inherited connective tissues - more than ‘just’ hypermobility
- Update on neuropsychiatric SLE
- Aging, senescence and osteoarthritis
- Inflammation and crystal diseases – what’s hot?
- Cartilage - heal thyself!
- Biological DMARDs in RA II
- Rheumatoid arthritis - prognosis, predictors and outcome II
- Update on new treatment options for psoriatic arthritis
- Rheumatoid arthritis - non biologic treatment and small molecules
- Preclinical models of arthritis and bone disease
- Progress in scleroderma and myositis
- Other orphan diseases
- Public health, health services, and health economics in RMDs
- Novel diagnostic and therapeutic approaches in paediatric rheumatic diseases
- Osteoporosis
- The new art of phenotyping and treating Sjön's syndrome
- Meniscus : an innocent bystander in osteoarthritis?
- SpA: Innovative techniques in spondyloarthritis research – Is there light at the end of the tunnel for our patients?
- Newly identified cell subsets driving disease pathogenesis
- Fractures, more than bone alone: the role of sarcopenia
- Clinical symposium axSpA: Treat-to-target in axSpA: myth or reality?
- New perspectives on therapeutic immune tolerance
- Pathological calcification in rheumatic diseases
- The cost-opportunity of screening: osteoporosis in the general population
- EFIS-EULAR - origin of autoantibodies
- Artificial intelligence and osteoarthritis
- Autoimmune diseases by abnormal T cell function
- Quantitative imaging
- Origin and role of myeloid cells during homeostasis and inflammation
- New technologies in translational rheumatology
- Science communication skills for young rheumatologists
- Abstracts Accepted for Oral Presentations*
- Late breaking abstracts
- COVID-19 abstracts
- Poster Presentations
- Thursday, 04 June 2020
- Posters
- Genomics, genetic basis of disease and functional genomics
- Adaptive immunity (T cells and B cells) in rheumatic diseases
- OA, aetiology, pathology and animal models
- Rheumatoid arthritis - aetiology, pathogenesis and animal models
- Rheumatoid arthritis - prognosis, predictors and outcome
- Rheumatoid arthritis - comorbidity and clinical aspects
- Rheumatoid arthritis - biological DMARDs
- Rheumatoid arthritis - non biologic treatment and small molecules
- SLE, Sjön’s and APS - etiology, pathogenesis and animal models
- SLE, Sjön’s and APS - clinical aspects (other than treatment)
- Vasculitis
- Scleroderma, myositis and related syndromes
- Spondyloarthritis - treatment
- Crystal diseases, metabolic bone diseases other than osteoporosis
- Basic and translational pain science
- Pain in rheumatic diseases, including fibromyalgia
- Back pain, mechanical musculoskeletal problems, local soft tissue disorders
- Basic and translational science in paediatric rheumatology
- Paediatric rheumatology
- Diagnostics and imaging procedures
- Public health, health services research, and health economics
- Rehabilitation
- Education
- Educational cases
- Posters
- Friday, 05 June 2020
- Posters
- Innate immunity in rheumatic diseases
- Rheumatoid arthritis - prognosis, predictors and outcome
- Rheumatoid arthritis - comorbidity and clinical aspects
- Rheumatoid arthritis - biological DMARDs
- Rheumatoid arthritis - non biologic treatment and small molecules
- SLE, Sjön’s and APS - clinical aspects (other than treatment)
- Vasculitis
- Scleroderma, myositis and related syndromes
- Spondyloarthritis - treatment
- Spondyloarthritis - clinical aspects (other than treatment)
- Psoriatic arthritis
- Bone diseases, including osteoporosis and osteoimmunology: aetiology, pathology and animal models
- Osteoarthritis
- Infection-related rheumatic diseases
- Basic and translational science in paediatric rheumatology
- Paediatric rheumatology
- Other orphan diseases
- Public health, health services research, and health economics
- Epidemiology, risk factors for disease or disease progression
- Validation of outcome measures and biomarkers
- Rehabilitation
- Posters
- Saturday, 06 June 2020
- Posters
- Rheumatoid arthritis - aetiology, pathogenesis and animal models
- Rheumatoid arthritis - prognosis, predictors and outcome
- Rheumatoid arthritis - comorbidity and clinical aspects
- Rheumatoid arthritis - biological DMARDs
- Rheumatoid arthritis - non biologic treatment and small molecules
- SLE, Sjön’s and APS - treatment
- SLE, Sjön’s and APS - clinical aspects (other than treatment)
- Vasculitis
- Systemic sclerosis, myositis and related syndromes - etiology, pathogenesis and animal models
- Scleroderma, myositis and related syndromes
- Spondyloarthritis - etiology, pathogenesis and animal models
- Spondyloarthritis - clinical aspects (other than treatment)
- Psoriatic arthritis
- Osteoporosis
- Basic and translational science in paediatric rheumatology
- Paediatric rheumatology
- Other orphan diseases
- Diagnostics and imaging procedures
- Epidemiology, risk factors for disease or disease progression
- Rehabilitation
- Posters
- Abstracts Accepted for Publication
- Genomics, genetic basis of disease and functional genomics
- Adaptive immunity (T cells and B cells) in rheumatic diseases
- Innate immunity in rheumatic diseases
- OA, aetiology, pathology and animal models
- Bone diseases, including osteoporosis and osteoimmunology: aetiology, pathology and animal models
- Rheumatoid arthritis - aetiology, pathogenesis and animal models
- Spondyloarthritis - etiology, pathogenesis and animal models
- SLE, Sjön’s and APS - etiology, pathogenesis and animal models
- Systemic sclerosis, myositis and related syndromes - etiology, pathogenesis and animal models
- Basic and translational science in paediatric rheumatology
- Basic and translational pain science
- Rheumatoid arthritis - prognosis, predictors and outcome
- Rheumatoid arthritis - comorbidity and clinical aspects
- Rheumatoid arthritis - biological DMARDs
- Rheumatoid arthritis - non biologic treatment and small molecules
- SLE, Sjön’s and APS - treatment
- SLE, Sjön’s and APS - clinical aspects (other than treatment)
- Vasculitis
- Scleroderma, myositis and related syndromes
- Spondyloarthritis - treatment
- Spondyloarthritis - clinical aspects (other than treatment)
- Psoriatic arthritis
- Osteoarthritis
- Osteoporosis
- Crystal diseases, metabolic bone diseases other than osteoporosis
- Infection-related rheumatic diseases
- Pain in rheumatic diseases, including fibromyalgia
- Back pain, mechanical musculoskeletal problems, local soft tissue disorders
- Paediatric rheumatology
- Other orphan diseases
- Diagnostics and imaging procedures
- Public health, health services research, and health economics
- Epidemiology, risk factors for disease or disease progression
- Validation of outcome measures and biomarkers
- Rehabilitation
- Education
- Educational cases
- Thursday, 04 June 2020
- Health Professionals in Rheumatology Abstracts
- Oral Presentations
- Abstracts Accepted for Oral Presentations*
- Poster Presentations
- Thursday, 04 June 2020
- Friday, 05 June 2020
- Posters
- HPR Epidemiology and public health (including prevention)
- HPR Interventions (educational, physical, social and psychological)
- HPR Interdisciplinary research
- HPR Patients’ perspectives, functioning and health (descriptive: qualitative or quantitative)
- HPR Service developments, innovation and economics in healthcare
- Posters
- Saturday, 06 June 2020
- Posters
- HPR Epidemiology and public health (including prevention)
- HPR Service developments, innovation and economics in healthcare
- HPR Interdisciplinary research
- HPR Interventions (educational, physical, social and psychological)
- HPR Patients’ perspectives, functioning and health (descriptive: qualitative or quantitative)
- HPR Professional education, training and competencies
- Posters
- Abstracts Accepted for Publication
- HPR Measuring health (development and measurement properties of PROs, tests, devices)
- HPR Epidemiology and public health (including prevention)
- HPR Interventions (educational, physical, social and psychological)
- HPR Patients’ perspectives, functioning and health (descriptive: qualitative or quantitative)
- HPR Service developments, innovation and economics in healthcare
- HPR Professional education, training and competencies
- HPR Interdisciplinary research
- People with Arthritis and Rheumatism in Europe Abstracts
- Oral Presentations